We hypothesized that the ventilatory threshold and sensitivity to carbon dioxide in the presence of hypoxia and hyperoxia during wakefulness would be increased following testosterone administration in pre-menopausal women. Additionally, we hypothesized that the sensitivity to carbon dioxide increases following episodic hypoxia and that this increase is enhanced after testosterone administration. Eleven females completed 4 modified carbon dioxide rebreathing trials before and after episodic hypoxia. Two rebreathing trials before and after episodic hypoxia were completed with oxygen levels sustained at 150 mmHg, the remaining trials were repeated while oxygen was maintained at 50 mmHg. The protocol was completed following 8-10 days of treatment with testosterone or placebo skin patches. Resting minute ventilation was greater following treatment with testosterone compared to placebo (testosterone -11.38 ± 0.43 vs. placebo -10.07 ± 0.36 L/min; p < 0.01). This increase was accompanied by an increase in the ventilatory sensitivity to carbon dioxide in the presence of sustained hyperoxia (VSCO2 hyperoxia ) compared to placebo (3.6 ± 0.5 vs. 2.9 ± 0.3; p < 0.03). No change in the ventilatory sensitivity to carbon dioxide in the presence of sustained hypoxia (VSCO2 hypoxia ) following treatment with testosterone was observed.
INTRODUCTION
The impact of testosterone on sleep apnea prevalence and severity in males has been recognized for over two decades (8; 30) . Pilot studies reported initially that the apnea/hypopnea index increased in hypogonadal men after testosterone administration (26; 33) , although the response to administration was variable. Nevertheless, Liu and colleagues (19) showed using a well controlled experimental design that testosterone administration exacerbated sleep apnea in older men. Elevated testosterone levels may also promote apnea in females since elevated androgen levels caused by polycystic ovarian syndrome is associated with a greater apnea/hypopnea index compared to healthy controls (15) . Furthermore, since free testosterone levels have been reported to rise across the menopausal transition (6) , it is possible that androgen levels may in part be responsible for the increase in the prevalence of apnea that has been reported in post compared to premenopausal females (36; 41) .
Elevated testosterone levels might impact on apnea severity in part by altering the ventilatory response to carbon dioxide. This response is characterized by a threshold which delineates the point at which ventilation increases linearly in response to increases in carbon dioxide. The threshold is referred to as the apneic threshold during sleep (10) and the ventilatory threshold during wakefulness (24) . The slope of the ventilatory response to carbon dioxide above the thresholds is a measure of ventilatory sensitivity (24) . Below the thresholds, ventilation does not respond to increases in carbon dioxide during sleep and wakefulness, although ventilation maybe sustained by arousal and behavioral stimuli during wakefulness (37) . Increasing ventilatory sensitivity and/or a shift of the ventilatory/apneic threshold closer to resting levels of carbon dioxide may promote apnea severity (10) .
The impact of elevated androgen levels on ventilatory control in females is not well established, since only one study to our knowledge has investigated this relationship. Zhou and colleagues (42) demonstrated during non-rapid eye movement (NREM) sleep that the application of testosterone resulted in a shift of the apneic threshold closer to resting levels of carbon dioxide and an increase in ventilatory sensitivity to a reduction in carbon dioxide levels (i.e. hypocapnia). Whether or not this change in sensitivity was largely a Page 3 of 26 consequence of modifications in metabolic rate or chemoreflex sensitivity was not determined. Additionally, the ventilatory response to stimuli typically experienced during and immediately following an apnea (i.e. hypercapnia and/or hypoxia) was not investigated. Consequently, inferences as to whether central and/or peripheral chemoreflex sensitivity was altered following testosterone administration were not possible. Lastly, the possibility that the results obtained were a consequence of an order effect could not be ruled out because of the experimental design.
In the present investigation we employed a cross-over randomized design to examine the ventilatory threshold and sensitivity to carbon dioxide in the presence of sustained hyperoxia and hypoxia, below and above the ventilatory threshold, during wakefulness in women following treatment with testosterone or placebo.
We hypothesized that the ventilatory threshold and ventilatory sensitivity to carbon dioxide in the presence of sustained hyperoxia (VSCO 2 hyperoxia ) would be principally impacted following treatment with testosterone in females, because this response has been consistently greater in mammals with elevated (e.g. males) compared to reduced (e.g. females/hypogonadal males) testosterone levels (1; 5; 17; 28; 31; 38; 40) .
In addition to the impact of testosterone on the ventilatory threshold and/or sensitivity, a variety of studies have suggested that these measures are also mutable following exposure to continuous or episodic hypoxia (18; 21; 22; 24; 27) . We showed recently that the ventilatory sensitivity to carbon dioxide in the presence of hypoxia (VSCO 2 hypoxia ) increased following exposure to episodic hypoxia (24) and that the increase was greater in males compared to females (27) . The greater increase observed in males following episodic hypoxia could be a consequence of testosterone levels. This possibility might have important implications for females with elevated androgen levels, since potential increases in the ventilatory response that may exist because of hormonal modifications could be further exacerbated by exposure to episodic hypoxia, which is a hallmark of obstructive sleep apnea. Thus, the second aim of our investigation was to determine whether treatment with testosterone leads to a greater increase in the VSCO 2 hyperoxia or VSCO 2 hypoxia after episodic hypoxia in women during wakefulness following treatment with testosterone compared to placebo.
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METHODS
Protocol overview
The Human Investigation Committees of Wayne State University School of Medicine and John D.
Dingell Veterans Affairs Medical Center approved the experimental protocol. Eleven healthy premenopausal women (age -24.9 ± 1.3 yrs, height -65.9 ± 0.7 inches, weight -137.9 ± 5.3 lbs) visited the laboratory on three occasions after informed consent was obtained. The subjects recruited were not on birth control pills or other forms of medication. Prior to each visit subjects were advised to have a minimum of 7 hours of sleep before the study and to fast for a minimum of 3 hours before visiting the laboratory. On each occasion subjects arrived at the same time of the day to account for the influence of circadian rhythms on the measured variables. During the first visit to the laboratory subjects underwent a physical examination and pregnancy test. Once the inclusion criteria (i.e. healthy and not pregnant) were fulfilled, subjects completed one rebreathing trial and were exposed to two 4-min episodes of hypoxia to ensure familiarization with the experimental protocol and apparatus. The subjects were then given either [8] [9] [10] testosterone (Androderm® Watson pharmaceuticals Inc.) or placebo patches (Watson pharmaceuticals Inc.) in a randomized fashion. The testosterone patch was a once-daily skin patch that delivered consistent and controlled concentrations of testosterone through the skin. The central drug delivery reservoir of the patch contained testosterone in powdered form dissolved in alcohol-based gel. The dosing strength used was 5 mg/day. The subjects were advised to put the patches on different areas of the body such as the back, abdomen, thigh and upper arm to reduce the chance of skin irritation induced by application of the patches to the same skin location. The placebo patches were similar in appearance to the testosterone patches so that the subjects were blinded. The first testosterone or placebo patch was administered at the onset of the menstrual cycle and a new patch was worn each day for 8-10 consecutive days. Thereafter, subjects came to the laboratory for a second visit.
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On the second visit to the laboratory, prior to completion of the protocol, 10 cc of venous blood was drawn into Vacutainer tubes with a clot activator (BD Diagnostics, Franklin Lakes, NJ). The sample collected was tested for the steroid hormones progesterone, estrogen, estradiol and testosterone.
Subsequently, subjects assumed a supine position and the required monitoring equipment was attached (see below for details regarding monitoring equipment). During the second visit four rebreathing trials were completed before and four rebreathing trials after exposure to episodic hypoxia. Thus, a total of eight rebreathing trials were completed. Two of the four rebreathing trials completed before or after episodic hypoxia occurred while oxygen was sustained at a partial pressure of end-tidal oxygen (P ET O 2 ) of 50 mmHg.
The remaining trials were completed with the oxygen level sustained at 150 mmHg. Prior to completing each rebreathing trial baseline measures of ventilation and P ET CO 2 were obtained. The episodic hypoxia protocol, completed while subjects were in the supine position, consisted of eight 4-min episodes of hypoxia separated by 5-min recovery periods. The first hypoxic episode was preceded by a 15 minute baseline period and the last hypoxic episode was followed by a 15 minute recovery period.
Once the experimental protocol was completed subjects were given another 8-10 patches that were either placebo or testosterone patches. Subjects who had previously received testosterone patches received placebo patches and visa versa. Subjects started wearing their second set of patches at the onset of the menstrual cycle. Consequently, subjects began wearing the second set of patches approximately one month after the second visit to the laboratory. After wearing the patches for 8-10 days subjects returned to the laboratory for a third visit. During the third visit to the laboratory the protocol completed by the subjects was identical to that described for the second laboratory visit.
Modified rebreathing protocol
A modified rebreathing protocol was employed to measure the ventilatory threshold and sensitivity to carbon dioxide before and after episodic hypoxia (12; 13; 24) . Each rebreathing trial was separated by 20-minutes of rest. During each rebreathing trial, the subjects initially breathed room air for 5 min, subsequently subjects hyperventilated for 5 min while being coached to maintain the end-tidal partial Page 6 of 26 pressure of carbon dioxide (P ET CO 2 ) between 20 and 25 Torr. This period of hyperventilation was employed to lower the stores of the carbon dioxide so that the point where ventilation begins to rise with increases in P ET CO 2 (i.e. the ventilatory threshold) could be delineated. After the desired P ET CO 2 was maintained for at least 5 min, subjects were switched from room air to a rebreathing bag. As mentioned, two hyperoxic (i.e. 150 mmHg) and 2 hypoxic (i.e. 50 mmHg) rebreathing trials were completed before as well as after episodic hypoxia. The P ET CO 2 in the bag at the start of the rebreathing experiment was 42 mmHg.
Rebreathing began at the end of expiration and was followed by three rapid and deep breaths that produced rapid equilibration of the carbon dioxide partial pressure in the bag, lungs and arterial blood to that of mixed venous blood. The presence of a plateau in carbon dioxide during the equilibration was a prerequisite for the continuation of the test and if a plateau was not observed after 3 deep breaths, the test was aborted. Rebreathing continued until P ET CO 2 increased at least 10 Torr above the threshold or the minute ventilation reached 100 liters/min. Conditions of quiet wakefulness were maintained and noise in the lab was minimized in order to reduce any behavioral stimuli that might affect breathing.
During the rebreathing trials the subjects wore a tight fitting mask. The mask was connected to a pneumotachograph (Model RSS100-HR, Hans Rudolph, Inc Kansas, MO, USA) that was used to monitor breath-by-breath changes in ventilation. The pneumotachograph was attached to one side of a three-way valve that allowed us to switch the subjects from room air to the rebreathing bag. The end-tidal oxygen and carbon dioxide were sampled from the pneumotachograph side of the three-way valve using oxygen and carbon dioxide analyzers (Model 17518 and Model 17515 -Vacumed Inc.). The end-tidal gas that was sampled for monitoring was returned to the bag during rebreathing. The oxygen level in the bag during rebreathing was maintained by a flow of oxygen that was computer controlled. If oxygen decreased below the desired threshold (50 or 150 mmHg), oxygen was immediately bled into the bag. The oxygen saturation was monitored using a pulse oximeter (Biox 3700, Ohmeda Corp.). A 16-bit analog to digital converter (AT-MIO-16XE-50, National Instruments) was used to digitize the analog signals for computer analysis using software specifically designed for this purpose. The software calculated the tidal volume, breathing frequency, ventilation and P ET O 2 and P ET CO 2 on a breath-by-breath basis.
Episodic hypoxia
During the episodic hypoxia, the subjects breathed through a face-mask that was attached to a twoway valve. The inspiratory port of the valve was connected to a stopcock. Subjects breathed either room air or from one of the bags attached to the stopcock. One of the bags contained 8% oxygen, balance nitrogen.
The other bag contained 100% oxygen. Prior to the first episode of hypoxia, subjects breathed room air for 15 minutes so that baseline values of minute ventilation and carbon dioxide could be determined.
Subsequently, subjects were exposed to eight 4-min episodes of hypoxia separated by 5 minutes of recovery. During the episodes of hypoxia the subjects inspired the gas mixture comprised of 8% oxygen/balance nitrogen. After the completion of every episode, hypoxia was abruptly terminated with a single breath of 100% oxygen to rapidly bring the P ET O 2 to the normoxic range. After the last episode of hypoxia (8th episode) respiration was monitored for 15 minutes.
Data Analysis
The data collected during the rebreathing trials was analyzed using a spreadsheet designed for this purpose. Prior to the analysis the three deep breaths that were required for equilibration in addition to sighs and swallows were excluded from further analysis. Minute ventilation was then plotted against P ET CO 2 .
The ventilation versus P ET CO 2 plot was divided into two segments. The first segment was characterized by a sustained level of ventilation in response to increases in carbon dioxide (i.e. basal ventilation). The second segment was characterized by a break-point followed by a linear increase in minute ventilation as the P ET CO 2 increased. The breakpoint was taken as a measure of the ventilatory threshold to carbon dioxide.
The threshold measured during the rebreathing trials during which P ET O 2 was sustained at 150 Torr was assumed to represent the central chemoreflex while the threshold measured while P ET O 2 was sustained at 50
Torr was assumed to be the central + peripheral chemoreflex threshold. The slope of the line fitted to minute ventilation after the threshold was taken as a measure of the ventilatory sensitivity to P ET CO 2 . The average 
Statistics
To examine the impact of testosterone and episodic hypoxia on chemoreflex sensitivity a two-way analysis of variance (ANOVA) with repeated measures in conjunction with Student-Newman-Keuls post hoc test was completed. The main factors were "treatment" and "episodic hypoxia". The levels of the main factors were "placebo vs. testosterone" and "before episodic hypoxia vs. after episodic hypoxia". A similar analysis was completed to determine the effect of testosterone and/or episodic hypoxia on the central or the central + peripheral chemoreflex thresholds. A two-way ANOVA in conjunction with Student-NewmanKeuls post hoc test was also employed to compare baseline ventilation, basal ventilation and the rate of rise of carbon dioxide during rebreathing measured throughout the placebo and testosterone studies. A paired ttest was used to compare the ventilatory response to episodic hypoxia and hormone levels between the placebo and testosterone trials. All results are presented as means ± standard error. A value of P 0.05 was considered significant. Figure 1 shows that serum testosterone concentration was significantly greater after testosterone administration compared to placebo (p < 0.003). In contrast, estrogen, 17-P estradiol and progesterone were unchanged following testosterone administration.
RESULTS
Baseline ventilation was increased after testosterone administration (testosterone -11.38 ± 0.43 vs.
placebo -10.07 ± 0.36 L/min; p < 0.01). The increase was a consequence of differences in breathing frequency (testosterone -17.6 ± 0.7 vs. placebo -16.9 ± 0.8 breaths/min; p < 0.03) and not tidal volume (testosterone -671.2 ± 26.1 vs. placebo -643.2 ± 20.9 ml; p > 0.2). Measures of P ET CO 2 were similar under both conditions (testosterone -40.3 ± 0.6 vs. placebo -39.7 ± 0.9 mmHg; p > 0.76).
In contrast to baseline minute ventilation, Fig. 2 shows that basal ventilation (i.e. ventilation below the ventilatory threshold during rebreathing trials) following testosterone administration was similar to placebo during carbon dioxide rebreathing trials completed in the presence of sustained hyperoxia ( Fig. 2A) and hypoxia (Fig. 2B) either before or after exposure to episodic hypoxia (hyperoxia -testosterone vs.
placebo -p > 0.75; hypoxia -testosterone vs. placebo -p > 0.30). Moreover, following testosterone or placebo treatment, basal ventilation before exposure to episodic hypoxia was similar to measures obtained after exposure during both the hyperoxic and hypoxic rebreathing trials (hyperoxia -before vs. after -p > 0.82; hypoxia -before vs. after -p > 0. 19) . No change in the ventilatory threshold to carbon dioxide in the presence of sustained hyperoxia (Fig. 3A) and hypoxia (Fig. 3B ) was evident after testosterone administration compared to placebo, before or after exposure to episodic hypoxia (hyperoxia -testosterone vs. placebo -p > 0.70; hypoxia -testosterone vs. placebo -p > 0.46). Additionally, the ventilatory thresholds measured before compared to after exposure to episodic hypoxia were similar following testosterone or placebo administration (Fig. 3) .
In contrast, a significant increase in the VSCO 2 hyperoxia was observed after testosterone administration compared to placebo (3.6 ± 0.5 vs. 2.9 ± 0.3; p < 0.03) before exposure to episodic hypoxia (Fig. 4A) . This increase was not accompanied by changes in metabolic rate during the rebreathing trials; since the rate of rise of carbon dioxide during the rebreathing trials completed under conditions of sustained hyperoxia were similar following placebo and testosterone administration (0.052 ± .002 mmHg/sec vs. 0.054 ± 0.002 mmHg/sec -p > 0.5). The VSCO 2 hypoxia after testosterone administration was similar to measures obtained under placebo conditions (Fig. 4B) either before or after exposure to episodic hypoxia (p > 0.83). Likewise, the ventilatory response to steady state isocapnic hypoxia following testosterone administration was similar to the response measured under placebo conditions (p > 0.99) (Fig. 5) In contrast, the ventilatory response to carbon dioxide in the presence of sustained hypoxia (Fig. 4B ) was greater after compared to before episodic hypoxia following administration of testosterone or placebo patches (p < 0.01).
DISCUSSION
The primary findings of our study are that the VSCO 2 hyperoxia was increased following administration of testosterone patches for 8-10 days in healthy females compared to placebo. Conversely, the VSCO 2 hypoxia was unaffected by testosterone administration. Additionally, our results showed that exposure to episodic hypoxia led to an increase in the VSCO 2 hypoxia , however the increase was independent of treatment with placebo or testosterone skin patches.
Impact of testosterone on baseline ventilation and the ventilatory response to carbon dioxide before exposure to episodic hypoxia
Our results showed that baseline ventilation increased after treatment with testosterone. Given that the studies were completed during wakefulness, the increase observed might have occurred because of changes in behavioral/arousal stimuli (37) . However, we believe this scenario is unlikely because we found that basal ventilation (i.e. ventilation below the ventilatory threshold), which is primarily influenced by behavioral/arousal stimuli (13) , was unaltered after treatment with testosterone. Similarly, the increase in baseline ventilation was not likely due to alterations in the ventilatory threshold, the VSCO 2 hypoxia or the Page 11 of 26 ventilatory response to isocapnic hypoxia measured during the episodic hypoxia protocol, since these variables remained unchanged following testosterone administration. In contrast, an increase in the VSCO 2 hyperoxia might have been principally responsible for the increase in baseline ventilation since it was increased following testosterone treatment.
Given our assumptions (see Data Analysis) the lack of an increase in the VSCO 2 hypoxia and the ventilatory response to isocapnic hypoxia suggests that the combined central + peripheral chemoreflex sensitivity and the peripheral chemoreflex alone remained unaltered following testosterone administration.
In contrast, the increase in VSCO 2hyperoxia suggests that testosterone impacted on one of the components comprising the central chemoreflex pathway (i.e. central chemoreceptors, medullary respiratory neurons, spinal motoneurons), particularly since the metabolic rate was similar before and after testosterone administration.
The impact of testosterone on the central chemoreflex is possible given that sex hormone receptors (i.e. testosterone and estrogen receptors) have been located in a number of regions in the central nervous system, including the hypoglossal nucleus, ventro-lateral nucleus tractus solitarius and spinal respiratory motoneurons (3; 4; 32). Testosterone might have impacted on the central chemoreflex directly or indirectly through conversion to estradiol via aromatase (16) . However, we have no evidence that testosterone impacted on the central chemoreflex via conversion to estradiol, since serum measures of estradiol and estrogen levels remained unaltered following testosterone administration. Nevertheless, unaltered serum hormonal levels cannot rule out that estrogen and progesterone levels were elevated within the central nervous system. The increase in VSCO 2 hyperoxia we observed is similar to the results of Zhou and colleagues (42) who reported that the ventilatory sensitivity to reductions in carbon dioxide below baseline values is increased during NREM sleep following testosterone administration in women. We have extended these findings by demonstrating directly that the change in ventilatory sensitivity is not a consequence of changes in metabolic rate or treatment order. Moreover, we have provided evidence which suggests that changes in ventilatory sensitivity observed in Zhou and colleagues study (42) were mediated primarily by alterations in central chemoreflex sensitivity. In contrast, our findings appear to be contradictory to our previously published results which showed that testosterone depression in males also led to an increase in the VSCO 2 hyperoxia (25) . However, the discrepancy between the two studies may be a consequence of different hormone profiles. The hormone profile induced for a 2 month time period in the males that participated in our previous study (25) resembled that of post-menopausal women (i.e. testosterone, estrogen, estradiol, luteinizing hormone and follicle stimulating hormone were suppressed). Thus, the suppression of other hormones may have been responsible for the increase in central chemoreflex sensitivity observed previously or the impact of testosterone on chemoreflex sensitivity is altered in the presence of variations in levels of other hormones.
The increase in the VSCO 2 hyperoxia that we observed was not coupled with alterations in the ventilatory threshold, which is in contrast to Zhou and colleagues (42) who reported both an increase in the apneic threshold and the ventilatory sensitivity to carbon dioxide. Further investigation is required to determine whether arousal state (i.e. wake versus sleep) and/or the methodology used to measure the ventilatory response to carbon dioxide (i.e. modified rebreathing of carbon dioxide in the presence of sustained hyperoxia during wakefulness versus normoxic hypocapnia induced by mechanical hyperventilation during sleep) might account for the difference. Conversely, treatment with testosterone for more than one week may be required to induce pervasive alterations in the ventilatory threshold. Indeed, we previously showed that suppressing testosterone for two months in males lead to alterations in both the ventilatory threshold during wakefulness and the apneic threshold during sleep (25) .
The increase in the VSCO 2hyperoxia that we observed after testosterone administration in healthy young females supports the premise that increased endogenous levels of testosterone in females, which occur in conjunction with ovarian tumors (11) , polycystic ovary syndromes (15; 39) or menopause (6), might lead to alterations in the ventilatory sensitivity to carbon dioxide. An increase in ventilatory sensitivity could lead to hyperventilation in the face of elevated carbon dioxide levels. This could lead ultimately to a reduction in carbon dioxide that extends below the apneic threshold during sleep leading to the development of a central apnea and possibly an obstructive apnea (2) . Thus an increase in ventilatory sensitivity to carbon dioxide could be responsible wholly, or in part, for the increased prevalence of sleep apnea that has been reported in these populations. However, the increase in ventilatory sensitivity in our study was caused by an increase in testosterone concentration (i.e. placebo -0.5 ± 0.06 vs. testosterone 6.1 ± 1.5 ng/ml) over a short time duration (i.e. 7 days) that was significantly greater than total testosterone concentration reported typically (e.g. 0.9-1.5 ng/ml) for patients suffering from polycystic ovary syndrome (20) . Thus, further study is required to determine whether smaller elevations in testosterone, typically characteristic of post-menopausal females or females with PCOS, sustained over a long duration of time induces increases in sensitivity similar to that observed in the present study.
Our findings also support the premise that the greater ventilatory response to carbon dioxide observed previously in males compared to females (1; 5; 17; 28; 34; 38; 40) is due in part to differences in testosterone levels. Conversely, our findings appear to dismiss previous suggestions by some investigators that gender differences in the ventilatory sensitivity to carbon dioxide are due solely to differences in height, weight, body mass index, lung volume or body surface area (1; 28; 38) . Thus, differences in the prevalence of sleep apnea between males and females may also be due in part to differences in the ventilatory sensitivity to carbon dioxide that may a consequence of hormonal differences.
Impact of testosterone on the ventilatory response to carbon dioxide after exposure to episodic hypoxia
An increase in the VSCO 2hypoxia was observed following exposure to episodic hypoxia. This finding is similar to our previous results (24; 27) . We also showed previously that the increased ventilatory response was greater in males compared to females (27) and we hypothesized that this gender difference was due to differences in sex hormones. Our results do not support this hypothesis since exposure to episodic hypoxia induced a similar increase in the VSCO 2hypoxia after treatment with placebo and testosterone patches. Consequently, a mechanism other than elevated levels of testosterone was likely responsible for the increase in the ventilatory response to hypoxia observed following episodic hypoxia/testosterone administration. Recent work has suggested that the release of reactive oxygen species following exposure to episodic hypoxia might be responsible for the enhancement of carotid body discharge which could lead to increases in the VSCO 2 hypoxia (29) . Whether gender differences exist within this mechanism is speculative and requires further investigation.
Our finding that the VSCO 2 hypoxia increased following exposure to episodic hypoxia suggests that chemoreflex sensitivity may not remain constant during sleep in individuals that experience repeated apneic episodes accompanied by hypoxemia, but rather may increase over the night as indicated by the work of Mahamed and colleagues (23) . If this is the case, and increases in chemoreflex sensitivity exacerbate sleep apnea, then apnea severity may increase from the beginning to the end of the night in individuals suffering from sleep apnea. This suggestion is supported by a few clinical studies (7; 9; 14; 35) that have reported that apnea severity increases from the beginning to the end of the night independent of other factors (e.g. sleep stage). Histograms showing the ventilatory sensitivity to carbon dioxide in the presence of sustained hyperoxia (A) and hypoxia (B) following administration of placebo (white bars) and testosterone (black bars) patches before and after exposure to episodic hypoxia. Note the ventilatory sensitivity to carbon dioxide in the presence of sustained hyperoxia was significantly greater following testosterone administration compared to placebo before exposure to episodic hypoxia. Additionally, note that the ventilatory sensitivity to carbon dioxide in the presence of sustained hypoxia was greater after compared to before episodic hypoxia. However this response was independent of whether subjects were treated with testosterone or placebo patches. * -significantly different from placebo p < 0.03; S -significantly different from before episodic hypoxia p < 0.01. 
